Skip to main content
Premium Trial:

Request an Annual Quote

Gentris Scores $5M VC Investment from Mitsui

NEW YORK, April 27 (GenomeWeb News) - Gentris has closed a $5 million funding round with Mitsui USA, the company said today. 


Gentris said that the new funding would allow it to continue to develop and distribute pharmacogenomic diagnostic testing kits.


The investment came one month after the FDA released it pharmacogenomics guidance, which Yoshi Maruoka, a senior vice president at Mitsui USA, said encouraged his company to invest in Gentris.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.